Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conservative surgery enhances late toxicities

Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
A ToledanoG Calais

Abstract

In 1996, a multicenter randomized study comparing after breast-conservative surgery, sequential vs concurrent adjuvant chemotherapy (CT) with radiation therapy (RT) was initiated (ARCOSEIN study). Seven hundred sixteen patients were included in this trial. After a median follow-up of 6.7 (4.3-9) years, we decided to prospectively evaluate the late effects of these two strategies. A total of 297 patients were asked to follow-up from the five larger including institutions. Seventy-two percent (214 patients) were eligible for late toxicity. After breast-conserving surgery with axillary dissection, patients were treated either with sequential treatment with CT first followed by RT (arm A) or CT administered concurrently with RT (arm B). In all patients, CT regimen combined mitoxantrone (12 mg/m(2)), 5-FU (500 mg/m(2)), and cyclophosphamide (500 mg/m(2)), 6 cycles (day 1-day 21). In arm B, patients received concurrently the first 3 cycles of CT with RT. In arm A, RT started 3 to 5 weeks after the 6th cycle of CT. Conventional RT was delivered to the whole breast using a 2 Gy-fraction protocol to a total dose of 50 Gy (+/-boost to the primary tumour bed). The assessment of toxicity was blinded to treatment and was graded by the radia...Continue Reading

References

Feb 20, 1992·The New England Journal of Medicine·C Schaake-KoningA Nijs
Jan 1, 1992·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J A van DongenJ Winter
Aug 1, 1991·Journal of the Royal Society of Health·M A Richards
Jul 1, 1991·International Journal of Radiation Oncology, Biology, Physics·A L AbnerJ R Harris
Mar 1, 1989·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·D SarrazinJ Lacour
Jul 1, 1989·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·S M BentzenM Overgaard
Mar 30, 1995·International Journal of Radiation Oncology, Biology, Physics·J J PavyH Bartelink
Mar 30, 1995·International Journal of Radiation Oncology, Biology, Physics·J O ArchambeauT Wasserman
Jul 1, 1996·International Journal of Radiation Oncology, Biology, Physics·D A MarkiewiczL J Solin
Dec 1, 1996·International Journal of Radiation Oncology, Biology, Physics·I TuressonA Odén
Apr 22, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G van TienhovenJ A van Dongen
Nov 26, 1999·International Journal of Radiation Oncology, Biology, Physics·A DubeyL N Shulman
Feb 8, 2000·International Journal of Radiation Oncology, Biology, Physics·P J FroudI A Olivotto
Apr 12, 2000·International Journal of Radiation Oncology, Biology, Physics·A TrottiW Curran
Oct 6, 2000·International Journal of Radiation Oncology, Biology, Physics·S JohanssonJ Denekamp
Apr 24, 2001·International Journal of Radiation Oncology, Biology, Physics·E TouboulM Schlienger
May 18, 2001·Cancer radiothérapie : journal de la Société française de radiothérapie oncologique·G Noël, J J Mazeron
Feb 1, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jenny HuangWilliam J Mackillop
Feb 8, 2003·International Journal of Radiation Oncology, Biology, Physics·Fabian FehlauerWinfried Alberti
Feb 28, 2003·International Journal of Radiation Oncology, Biology, Physics·Ulrike HoellerWinfried Alberti
Mar 26, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C FaulV Vogel
May 9, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·W E FietsH Struikmans
Aug 7, 2003·Seminars in Radiation Oncology·Soren M BentzenJacqueline Williams
Dec 6, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fabrice DenisGilles Calais
Dec 6, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andy Trotti, Soren M Bentzen
Jun 26, 2004·Cancer radiothérapie : journal de la Société française de radiothérapie oncologique·D LerougeM Jamali
Mar 9, 2005·International Journal of Radiation Oncology, Biology, Physics·Johnny KaoRuth Heimann
Apr 9, 2005·International Journal of Radiation Oncology, Biology, Physics·François CampanaAlain Fourquet
Apr 15, 2008·International Journal of Radiation Oncology, Biology, Physics·Theodore E Yaeger

❮ Previous
Next ❯

Citations

May 21, 2011·Cancer radiothérapie : journal de la Société française de radiothérapie oncologique·C BourgierM-C Vozenin
May 2, 2013·The Cochrane Database of Systematic Reviews·Brigid E HickeyMargot Lehman
Aug 2, 2020·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·Marc D PirothUNKNOWN Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO)

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.